ZA200801696B - Heparin compositions and selection inhibition - Google Patents
Heparin compositions and selection inhibitionInfo
- Publication number
- ZA200801696B ZA200801696B ZA200801696A ZA200801696A ZA200801696B ZA 200801696 B ZA200801696 B ZA 200801696B ZA 200801696 A ZA200801696 A ZA 200801696A ZA 200801696 A ZA200801696 A ZA 200801696A ZA 200801696 B ZA200801696 B ZA 200801696B
- Authority
- ZA
- South Africa
- Prior art keywords
- heparin compositions
- selection inhibition
- inhibition
- selection
- heparin
- Prior art date
Links
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title 1
- 229960002897 heparin Drugs 0.000 title 1
- 229920000669 heparin Polymers 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
- G01N2333/70564—Selectins, e.g. CD62
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
- G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/224—Haemostasis or coagulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70189305P | 2005-07-22 | 2005-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200801696B true ZA200801696B (en) | 2009-08-26 |
Family
ID=37683833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200801696A ZA200801696B (en) | 2005-07-22 | 2006-07-21 | Heparin compositions and selection inhibition |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20070021378A1 (xx) |
| EP (1) | EP1906974A4 (xx) |
| JP (1) | JP2009507209A (xx) |
| CN (1) | CN101583273A (xx) |
| AU (1) | AU2006272780A1 (xx) |
| CA (1) | CA2616166A1 (xx) |
| IL (1) | IL188936A0 (xx) |
| MX (1) | MX2008000974A (xx) |
| WO (1) | WO2007014049A2 (xx) |
| ZA (1) | ZA200801696B (xx) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8119159B2 (en) * | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| US7658938B2 (en) * | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| US20070148228A1 (en) * | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
| US20120295344A1 (en) * | 2006-08-25 | 2012-11-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Stem Cell Fusion Model of Carcinogenesis |
| SG152229A1 (en) * | 2005-08-25 | 2009-05-29 | Univ Arizona | Stem cell fusion model of carcinogenesis |
| BRPI0710503A2 (pt) * | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral |
| WO2009059284A2 (en) | 2007-11-02 | 2009-05-07 | Momenta Pharmaceuticals, Inc. | Non-anticoagulant polysaccharide compositions |
| WO2009073911A1 (en) * | 2007-12-10 | 2009-06-18 | Mater Medical Research Institute | Treatment and prophylaxis |
| JP5671451B2 (ja) * | 2008-05-07 | 2015-02-18 | メリオン・リサーチ・Iii・リミテッド | GnRH関連化合物の組成物および調製プロセス |
| WO2010099255A1 (en) * | 2009-02-25 | 2010-09-02 | Merrion Research Iii Limited | Composition and drug delivery of bisphosphonates |
| EP2419736B1 (en) * | 2009-04-16 | 2014-01-29 | Momenta Pharmaceuticals, Inc. | Methods of assessing activity of a polysaccharide composition |
| US20110182985A1 (en) * | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| WO2011120033A1 (en) * | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
| JP5982361B2 (ja) | 2010-04-16 | 2016-08-31 | モメンタ ファーマシューティカルズ インコーポレイテッド | 組織標的化方法 |
| US10321841B2 (en) * | 2010-05-26 | 2019-06-18 | Flint Hills Scientific, Llc | Quantitative multivariate analysis of seizures |
| JP5905455B2 (ja) | 2010-06-17 | 2016-04-20 | モメンタ ファーマシューティカルズ インコーポレイテッド | 発毛を促進する方法および組成物 |
| WO2012045114A1 (en) * | 2010-10-07 | 2012-04-12 | The University Of Queensland | Agents and methods for treating hematologic conditions |
| JP2014501784A (ja) | 2011-01-07 | 2014-01-23 | メリオン・リサーチ・Iii・リミテッド | 経口投与用の鉄の医薬組成物 |
| CN102192978B (zh) * | 2011-03-15 | 2013-09-04 | 中国科学院武汉病毒研究所 | 评价作用于体内粘膜的药物和外源物安全性的方法及应用 |
| WO2013095215A1 (en) * | 2011-12-19 | 2013-06-27 | Dilaforette Ab | Low anticoagulant heparins |
| DK2794665T3 (da) * | 2011-12-19 | 2018-01-29 | Dilafor Ab | Ikke-antikoagulative glycosaminoglycaner omfattende disaccharid-gentagelsesenhed og medicinsk anvendelse deraf |
| KR102165348B1 (ko) | 2012-05-09 | 2020-10-14 | 캔텍스 파마슈티칼즈, 인크. | 골수억제의 치료 |
| SI2928476T1 (en) | 2012-12-07 | 2018-06-29 | Glycomimetics, Inc. | COMPONENTS, INSTALLATIONS AND PROCEDURES OF THE APPLICATION OF E-SELECTINE OF ANTAGONISTS FOR THE MOBILIZATION OF HEMATOPOETIC CELLS |
| US10016449B2 (en) | 2013-05-28 | 2018-07-10 | Momenta Pharmaceuticals, Inc. | Pharmaceutical compositions |
| GB2515315A (en) | 2013-06-19 | 2014-12-24 | Dilafor Ab | New Processes |
| AU2014340238A1 (en) * | 2013-10-22 | 2016-05-05 | Cantex Pharmaceuticals, Inc. | Methods of treating and preventing radiation damage |
| DK3227310T3 (da) | 2014-12-03 | 2019-09-30 | Glycomimetics Inc | Heterobifunktionelle inhibitorer af e-selektiner og cxcr4-kemokin-receptorer |
| US10265384B2 (en) | 2015-01-29 | 2019-04-23 | Novo Nordisk A/S | Tablets comprising GLP-1 agonist and enteric coating |
| EP3258941A4 (en) | 2015-02-17 | 2018-09-26 | Cantex Pharmaceuticals, Inc. | Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction |
| US11291678B2 (en) | 2016-03-02 | 2022-04-05 | Glycomimetics, Inc | Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin |
| US11433086B2 (en) | 2016-08-08 | 2022-09-06 | Glycomimetics, Inc. | Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4 |
| CN117298287A (zh) | 2016-10-07 | 2023-12-29 | 糖模拟物有限公司 | 高效的多聚体e-选择蛋白拮抗剂 |
| JP7272956B2 (ja) | 2017-03-15 | 2023-05-12 | グリコミメティクス, インコーポレイテッド | E-セレクチンアンタゴニストとしてのガラクトピラノシル-シクロヘキシル誘導体 |
| US11712446B2 (en) | 2017-11-30 | 2023-08-01 | Glycomimetics, Inc. | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
| KR20200104889A (ko) | 2017-12-29 | 2020-09-04 | 글리코미메틱스, 인크. | E-셀렉틴 및 갈렉틴-3의 이종이기능성 억제제 |
| CN111867601A (zh) | 2018-03-05 | 2020-10-30 | 糖模拟物有限公司 | 用于治疗急性髓系白血病及相关病症的方法 |
| US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
| EP4103196A4 (en) * | 2020-02-10 | 2024-06-05 | University of Utah Research Foundation | HIGH MOLECULAR WEIGHT HEPARIN COMPOSITIONS AND METHODS FOR DIAGNOSIS, TREATMENT AND MONITORING EOSINOPHIL-MEDIATED INFLAMMATORY DISEASES |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3510561A (en) * | 1965-05-20 | 1970-05-05 | Canada Packers Ltd | Sulfone-enhanced heparin absorption through mucous membranes |
| FR2374910A1 (fr) * | 1976-10-23 | 1978-07-21 | Choay Sa | Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations |
| US4654327A (en) * | 1982-04-21 | 1987-03-31 | Research Corp. | Quaternary ammonium complexes of heparin |
| DE3237814A1 (de) * | 1982-10-12 | 1984-04-12 | Warner-Lambert Co., 07950 Morris Plains, N.J. | Wasserfreie emulsionen und verwendung derselben |
| DE3331009A1 (de) * | 1983-08-27 | 1985-03-14 | Basf Ag, 6700 Ludwigshafen | Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat |
| US4545161A (en) * | 1984-03-21 | 1985-10-08 | Marmet Corp. | Glazed curtain wall construction |
| US4703042A (en) * | 1984-05-21 | 1987-10-27 | Bodor Nicholas S | Orally active heparin salts containing multivalent cationic units |
| US4994439A (en) * | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
| US5464778A (en) * | 1989-03-08 | 1995-11-07 | Board Of Regents Of The University Of Oklahoma | Glycoprotein ligand for P-selectin and methods of use thereof |
| CA2108266C (en) * | 1991-04-19 | 2003-06-03 | Albert J. Owen | Convertible microemulsion formulations |
| US5688761A (en) * | 1991-04-19 | 1997-11-18 | Lds Technologies, Inc. | Convertible microemulsion formulations |
| CZ232593A3 (en) * | 1991-05-02 | 1994-07-13 | Yeda Res & Dev | Pharmaceutical preparation for preventing and/or therapy of pathological states |
| US6210671B1 (en) * | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| US5527785A (en) * | 1993-05-14 | 1996-06-18 | The Regents Of The University Of California | Selectin receptor modulating compositions |
| SE9302135D0 (sv) * | 1993-06-18 | 1993-06-18 | Kabi Pharmacia Ab | New pharmaceutical composition |
| US5622701A (en) * | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
| GB9415739D0 (en) * | 1994-07-30 | 1994-09-21 | Scimat Ltd | Gel wound dressing |
| US6428782B1 (en) * | 1997-05-23 | 2002-08-06 | Hadasit Medical Research Services And Development Ltd. | Non-myeloablative tolerogenic treatment |
| US6596705B1 (en) * | 1998-02-09 | 2003-07-22 | The Regents Of The University Of California | Inhibition of L-selectin and P-selection mediated binding using heparin |
| US6908907B2 (en) * | 2002-04-22 | 2005-06-21 | El-Naggar Mawaheb M. | Prevention and treatment of tumor growth, metastasis, and thromboembolic complications in cancer patients |
-
2006
- 2006-07-21 CN CNA2006800325191A patent/CN101583273A/zh active Pending
- 2006-07-21 WO PCT/US2006/028404 patent/WO2007014049A2/en not_active Ceased
- 2006-07-21 JP JP2008522999A patent/JP2009507209A/ja active Pending
- 2006-07-21 CA CA002616166A patent/CA2616166A1/en not_active Abandoned
- 2006-07-21 US US11/491,388 patent/US20070021378A1/en not_active Abandoned
- 2006-07-21 EP EP06800207A patent/EP1906974A4/en not_active Withdrawn
- 2006-07-21 MX MX2008000974A patent/MX2008000974A/es unknown
- 2006-07-21 ZA ZA200801696A patent/ZA200801696B/xx unknown
- 2006-07-21 AU AU2006272780A patent/AU2006272780A1/en not_active Abandoned
-
2008
- 2008-01-22 IL IL188936A patent/IL188936A0/en unknown
-
2009
- 2009-12-03 US US12/630,106 patent/US20100081630A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009507209A (ja) | 2009-02-19 |
| AU2006272780A1 (en) | 2007-02-01 |
| US20070021378A1 (en) | 2007-01-25 |
| CA2616166A1 (en) | 2007-02-01 |
| US20100081630A1 (en) | 2010-04-01 |
| WO2007014049A3 (en) | 2009-04-30 |
| WO2007014049A2 (en) | 2007-02-01 |
| CN101583273A (zh) | 2009-11-18 |
| IL188936A0 (en) | 2008-04-13 |
| MX2008000974A (es) | 2008-03-27 |
| EP1906974A2 (en) | 2008-04-09 |
| EP1906974A4 (en) | 2010-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200801696B (en) | Heparin compositions and selection inhibition | |
| IL191572A0 (en) | Pestcidal compositions | |
| IL186721A0 (en) | Bioenhanced compositions | |
| GB0515052D0 (en) | Organosiloxane compositions | |
| GB0503337D0 (en) | Compositions | |
| ZA200904425B (en) | Nemathical compositions | |
| EP1718714A4 (en) | COMPOSITIONS CONTAINING A PLOTTER | |
| IL186093A0 (en) | Lignan-containing compositions | |
| GB0506939D0 (en) | Organosiloxane compositions | |
| GB0405406D0 (en) | Anti-vaginitis compositions | |
| GB0526283D0 (en) | Compositions | |
| GB0501365D0 (en) | Compositions | |
| GB0524128D0 (en) | Compositions | |
| IL172896A0 (en) | Cxcr4 inhibition | |
| GB0517053D0 (en) | Shelving | |
| ZA200709913B (en) | Bioenhanced compositions | |
| ZA200701197B (en) | Compositions | |
| GB0410140D0 (en) | Compositions | |
| GB0526282D0 (en) | Compositions | |
| GB0501348D0 (en) | Compositions and methods | |
| GB0420627D0 (en) | Monoglyceride-containing compositions | |
| EP1872684A4 (en) | SHELF SYSTEM | |
| GB0501364D0 (en) | Compositions | |
| PL1787516T3 (pl) | Kompozycja do hamowania kiełkowania | |
| GB0506065D0 (en) | Compositions |